Evidence map›Paper›PMID 30134537›Full record

ReviewPharmaceutics2018

Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability.

Maria Rosa Gigliobianco, Cristina Casadidio, Roberta Censi, Piera Di Martino

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria Rosa GigliobiancoSchool of Pharmacy, University of Camerino, via S. Agostino, 1, 62032 Camerino, Italy. maria.gigliobianco@unicam.it.ORCID 0000-0002-9699-4673
Cristina CasadidioSchool of Pharmacy, University of Camerino, via S. Agostino, 1, 62032 Camerino, Italy. cristina.casadidio@unicam.it.ORCID 0000-0002-3925-7087
Roberta CensiSchool of Pharmacy, University of Camerino, via S. Agostino, 1, 62032 Camerino, Italy. roberta.censi@unicam.it.
Piera Di MartinoSchool of Pharmacy, University of Camerino, via S. Agostino, 1, 62032 Camerino, Italy. piera.dimartino@unicam.it.ORCID 0000-0002-7657-3556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many approaches have been developed over time to overcome the bioavailability limitations of poorly soluble drugs. With the advances in nanotechnology in recent decades, science and industry have been approaching this issue through the formulation of drugs as nanocrystals, which consist of "pure drugs and a minimum of surface active agents required for stabilization". They are defined as "carrier-free submicron colloidal drug delivery systems with a mean particle size in the nanometer range, typically between 10⁻800 nm". The primary importance of these nanoparticles was the reduction of particle size to nanoscale dimensions, with an increase in the particle surface area in contact with the dissolution medium, and thus in bioavailability. This approach has been proven successful, as demonstrated by the number of such drug products on the market. Nonetheless, despite the definition that indicates nanocrystals as a "carrier-free" system, surface active agents are necessary to prevent colloidal particles aggregation and thus improve stability. In addition, in more recent years, nanocrystal properties and technologies have attracted the interest of researchers as a means to obtain colloidal particles with modified biological properties, and thus their interest is now also addressed to modify the drug delivery and targeting. The present work provides an overview of the achievements in improving the bioavailability of poorly soluble drugs according to their administration route, describes the methods developed to overcome physicochemical and stability-related problems, and in particular reviews different stabilizers and surface agents that are able to modify the drug delivery and targeting.

Indexed as

drug deliverydrug targetingnanocrystalsnanotechnologypoorly soluble drugstability

Identifiers

PMID30134537
PMCPMC6161002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.